secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0000012208-24-000005
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 2.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad enters $200M credit facility; CEO Schwartz appointed interim CFO after Daskal departure
--------------------------------------------------------------------------------

- New $200M revolving credit facility with Wells Fargo, matures Feb 13, 2029; replaces prior $200M facility.
- CFO Ilan Daskal resigned effective Nov 6, 2023; CEO Norman Schwartz appointed interim principal financial officer on Feb 9, 2024.
- Facility includes leverage ratio covenant of 3.50x; interest rates based on SOFR plus margin.
- Outstanding obligations under prior credit agreement repaid in full on Feb 14, 2024 with no penalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000005/0000012208-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000005/bio-20240209.htm
  HTML page:      https://secwatch.observer/filing/0000012208-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer